叶平教授:糖尿病心血管病风险管理进入全程疾病管理时代

2019-10-16 卢芳 中国循环杂志

10月13日,在第六届阿斯利康心血管高峰论坛上,解放军总医院叶平教授指出,根据最新的欧洲糖尿病管理相关指南,对于合并动脉粥样硬化型心血管病或心血管高风险2型糖尿病患者,SGLT2抑制剂已超越二甲双胍,成为首选药物。虽然糖尿病显着增加高血压、冠心病和心衰患者的心血管事件风险,但在降糖治疗方面,大量研究证实,传统降糖药物未能改善糖尿病患者的心血管结局。而此时,SGLT2抑制剂横空出世。基于多项研究发现

10月13日,在第六届阿斯利康心血管高峰论坛上,解放军总医院叶平教授指出,根据最新的欧洲糖尿病管理相关指南,对于合并动脉粥样硬化型心血管病或心血管高风险2型糖尿病患者,SGLT2抑制剂已超越二甲双胍,成为首选药物。

虽然糖尿病显着增加高血压、冠心病和心衰患者的心血管事件风险,但在降糖治疗方面,大量研究证实,传统降糖药物未能改善糖尿病患者的心血管结局。

而此时,SGLT2抑制剂横空出世。基于多项研究发现,与传统口服降糖药相比,SGLT2抑制剂不仅降糖疗效好,有明确心血管获益,而且还可保护肾脏、安全性良好,还有降压、减重和降尿酸等兼顾多重危险因素的功效,堪称全程疾病管理

我国约有7000万心血管疾病患者合并糖尿病,中国3B研究还发现,1/3中国糖尿病患者病程超过10年,72%糖尿病患者合并高血压或高血脂。

她认为,该药的问世,也是我国糖尿病患者的福音。

中国2型糖尿病防治指南(2017版)指出,SGLT2抑制剂可降低HbA1c 0.5%-1.0%,单独服用不增加低血糖风险,可降低体重、降低收缩压、降低TG、升高HDL-C。

SGLT2抑制剂临床合理应用中国专家建议指出,SGLT2抑制剂降糖疗效确切,无低血糖风险,减轻体重,降低血压,可能有心血管及糖尿病肾病保护作用,满足了当前糖尿病治疗中部分未被满足的要求。

达格列净作为SGLT2抑制剂的代表药物,经DECLARE试验和DAPA-HF试验等研究证实,可通过降低心脏前后负荷、改善心肌重构、改善心脏能量代谢等多种途径实现心脏保护。达格列净能够24小时有效、平稳降糖,在更广泛早期人群中实现全面心脏保护,早联用早获益,而且总体安全性良好,不增加低血糖风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644795, encodeId=beac1644e9559, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jan 05 02:39:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893843, encodeId=6165189384341, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Apr 13 19:39:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804284, encodeId=96431804284a7, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Wed Nov 13 18:39:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542271, encodeId=946315422e189, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Fri Oct 18 06:39:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042772, encodeId=35271042e7238, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 16 18:39:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644795, encodeId=beac1644e9559, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jan 05 02:39:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893843, encodeId=6165189384341, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Apr 13 19:39:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804284, encodeId=96431804284a7, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Wed Nov 13 18:39:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542271, encodeId=946315422e189, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Fri Oct 18 06:39:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042772, encodeId=35271042e7238, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 16 18:39:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644795, encodeId=beac1644e9559, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jan 05 02:39:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893843, encodeId=6165189384341, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Apr 13 19:39:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804284, encodeId=96431804284a7, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Wed Nov 13 18:39:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542271, encodeId=946315422e189, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Fri Oct 18 06:39:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042772, encodeId=35271042e7238, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 16 18:39:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644795, encodeId=beac1644e9559, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jan 05 02:39:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893843, encodeId=6165189384341, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Apr 13 19:39:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804284, encodeId=96431804284a7, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Wed Nov 13 18:39:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542271, encodeId=946315422e189, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Fri Oct 18 06:39:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042772, encodeId=35271042e7238, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 16 18:39:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1644795, encodeId=beac1644e9559, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sun Jan 05 02:39:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893843, encodeId=6165189384341, content=<a href='/topic/show?id=33a6e0716f1' target=_blank style='color:#2F92EE;'>#疾病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70716, encryptionId=33a6e0716f1, topicName=疾病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Mon Apr 13 19:39:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804284, encodeId=96431804284a7, content=<a href='/topic/show?id=5153e6706d3' target=_blank style='color:#2F92EE;'>#糖尿病心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76706, encryptionId=5153e6706d3, topicName=糖尿病心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Wed Nov 13 18:39:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542271, encodeId=946315422e189, content=<a href='/topic/show?id=863d10089e30' target=_blank style='color:#2F92EE;'>#风险管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100897, encryptionId=863d10089e30, topicName=风险管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a78313401027, createdName=膀胱癌, createdTime=Fri Oct 18 06:39:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042772, encodeId=35271042e7238, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 16 18:39:00 CST 2019, time=2019-10-16, status=1, ipAttribution=)]
    2019-10-16 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

人工智能助力医疗健康,应用前景十分值得期待

近年来,人工智能在医疗健康领域的应用越来越广泛,医疗行业越来越多地采用这一先进技术来改善患者就医体验,提高医疗流程效率。人工智能已经跨越了医学方面的许多核心领域,从诊断到健康治疗,再到智能设备。可以说,人工智能技术已经成为医疗健康行业的有力辅助和支撑。正如我国著名学者周海中教授曾经指出的那样:“随着社会的发展和科技的进步,人工智能技术将在医疗健康领域大显身手;其成果会不断涌现,应用前景令人期待

这位已去世的研究者,有20多项研究被质疑有重大问题!

近期公布的一份报告显示, 1997年已去世的Hans Eysenck,他发表过的20多篇论文是“不安全的(unsafe)”。其实多年来,他的研究一直都受到质疑,因为很多研究的发现听上去就让人难以置信,例如,“阅读疗法(bibliotherapy)”可以显着降低癌症死亡风险。Hans Eysenck近期发表的这份调查报告是由Hans Eysenck的前单位组织开展,报告指出[1]:早在20世纪80年

研究:走路变慢,是衰老信号!

近日,一项来自美国杜克大学的研究表明,45岁时走路变慢,就提示这个人变老了。“一个人45岁时走路变慢,与身体多器官系统老化加速和脑容量变小、皮质变薄有关。”研究者介绍说。研究显示,走路慢与肺、牙齿、免疫系统变老都有关,最让人凉凉的是,走慢了,大脑和脸蛋也变老,也就是说认知变差,脸显老。此外研究者还发现,45岁时走路慢不慢,3岁时就能判断。3岁时智商、理解能力、情绪控制能力等差的人,通常在45岁时走

吃梨也相当于吃他汀!汇总分析称:多吃苹果或梨,可预防心血管病

以前有研究发现,50岁以上老人每天吃一个苹果,患心脏病或中风的风险就能降低12%。媒体则报道称,每天一个苹果,就像吃他汀。那么吃梨是否也有同样的功效?最近一项研究发现,吃梨也是可以的。观察性研究的结果显示,多吃苹果或梨,可显着降低多种疾病的死亡风险,包括急性冠脉综合征风险、脑血管病、心血管死亡、2型糖尿病和全因死亡风险。但研究发现,吃苹果和梨较多的人,体重、血糖、血压以及血脂指标均没有一致的下降。

1.73亿人有精神疾病 小心身体的报警信号

今天是世界精神卫生日。著名医学杂志《柳叶刀》一项最新研究指出,中国大约1.73亿人有精神疾病,包括焦虑、抑郁和强迫症等,其中1.58亿人从未接受过专业治疗。相关专家指出:失眠、焦虑、性格改变等都是身体发出的“报警信号”。据悉,为缓解病患的心理压力,我市有医院专门成立心理护理学组,让每个病患入院时接受心理痛苦评估后接受一定的心理治疗,让健康的心理利于病情的恢复。南京脑科医院儿童心理卫生研究中心主任医

《精神病学》:年轻时收入下降将影响大脑健康!

近日,世界知名科学文刊《精神病学》发表了一项新的研究报告:年轻时经历过收入下降25%以及25%以上的人,在中年时期更容易出现精神问题。这项研究结果是由法国国家健康与医学研究院得出的,研究人员在1990年到2020年长达20年的长期深入研究中,对3287位初始年龄为23岁到35岁之间的志愿者进行了跟踪调查。这项试验的志愿者们,每隔3年或者5年就会反馈一次自己家庭的税前年收入。在这3287,名志愿者中